Toth Financial Advisory Corp Buys 5,905 Shares of DexCom, Inc. (NASDAQ:DXCM)

Toth Financial Advisory Corp boosted its stake in DexCom, Inc. (NASDAQ:DXCM) by 870.9% during the 1st quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,583 shares of the medical device company’s stock after acquiring an additional 5,905 shares during the period. Toth Financial Advisory Corp’s holdings in DexCom were worth $913,000 at the end of the most recent quarter.

Other institutional investors have also added to or reduced their stakes in the company. Cary Street Partners Investment Advisory LLC raised its position in shares of DexCom by 11.1% during the third quarter. Cary Street Partners Investment Advisory LLC now owns 1,153 shares of the medical device company’s stock worth $108,000 after purchasing an additional 115 shares during the period. CX Institutional acquired a new position in shares of DexCom during the fourth quarter worth approximately $286,000. Bank of New Hampshire acquired a new position in shares of DexCom during the first quarter worth approximately $1,508,000. abrdn plc raised its position in shares of DexCom by 21.1% during the fourth quarter. abrdn plc now owns 380,535 shares of the medical device company’s stock worth $47,221,000 after purchasing an additional 66,348 shares during the period. Finally, Cerity Partners LLC raised its position in shares of DexCom by 5,791.0% during the fourth quarter. Cerity Partners LLC now owns 463,973 shares of the medical device company’s stock worth $57,574,000 after purchasing an additional 456,097 shares during the period. 97.75% of the stock is currently owned by institutional investors.

Insider Transactions at DexCom

In other news, EVP Michael Jon Brown sold 659 shares of the stock in a transaction on Friday, June 28th. The stock was sold at an average price of $114.29, for a total transaction of $75,317.11. Following the completion of the transaction, the executive vice president now owns 66,901 shares in the company, valued at approximately $7,646,115.29. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. In related news, EVP Michael Jon Brown sold 659 shares of the stock in a transaction dated Friday, June 28th. The stock was sold at an average price of $114.29, for a total transaction of $75,317.11. Following the sale, the executive vice president now owns 66,901 shares of the company’s stock, valued at approximately $7,646,115.29. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, EVP Sadie Stern sold 427 shares of the stock in a transaction dated Monday, June 10th. The stock was sold at an average price of $115.05, for a total value of $49,126.35. Following the sale, the executive vice president now directly owns 75,877 shares in the company, valued at approximately $8,729,648.85. The disclosure for this sale can be found here. In the last 90 days, insiders sold 55,735 shares of company stock worth $7,619,347. 0.30% of the stock is owned by company insiders.

Analysts Set New Price Targets

A number of equities analysts have recently weighed in on DXCM shares. StockNews.com lowered DexCom from a “buy” rating to a “hold” rating in a research report on Monday, June 10th. UBS Group increased their price target on DexCom from $153.00 to $163.00 and gave the company a “buy” rating in a research report on Wednesday, April 10th. Canaccord Genuity Group increased their price target on DexCom from $144.00 to $145.00 and gave the company a “buy” rating in a research report on Friday, April 26th. Citigroup increased their price target on DexCom from $148.00 to $161.00 and gave the company a “buy” rating in a research report on Wednesday, April 3rd. Finally, Royal Bank of Canada assumed coverage on DexCom in a research report on Tuesday, March 12th. They issued an “outperform” rating and a $165.00 price target for the company. Four investment analysts have rated the stock with a hold rating, eleven have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $140.33.

DexCom Stock Down 1.0 %

Shares of NASDAQ:DXCM opened at $113.38 on Friday. The company has a debt-to-equity ratio of 1.08, a current ratio of 2.90 and a quick ratio of 2.53. The company has a market capitalization of $45.09 billion, a PE ratio of 73.15, a price-to-earnings-growth ratio of 2.77 and a beta of 1.22. DexCom, Inc. has a 1 year low of $74.75 and a 1 year high of $142.00. The business has a fifty day moving average price of $123.14 and a two-hundred day moving average price of $125.70.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings results on Thursday, April 25th. The medical device company reported $0.32 earnings per share for the quarter, topping the consensus estimate of $0.27 by $0.05. The company had revenue of $921.00 million during the quarter, compared to the consensus estimate of $911.20 million. DexCom had a return on equity of 31.01% and a net margin of 16.82%. Analysts forecast that DexCom, Inc. will post 1.78 earnings per share for the current year.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company provides its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include Dexcom G6 and Dexcom G7, integrated CGM systems for diabetes management; Dexcom Share, a remote monitoring system; Dexcom Real-Time API, which enables authorized third-party software developers to integrate real-time CGM data into their digital health apps and devices; and Dexcom ONE, that is designed to replace finger stick blood glucose testing for diabetes treatment decisions.